We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues New Guidance on Priority Review Vouchers
FDA Issues New Guidance on Priority Review Vouchers
Drug products seeking an FDA designation as a medical countermeasure — defined as products used to diagnose, prevent or treat conditions associated with chemical, biological, radiological and nuclear threats — must not be previously approved for another indication, the agency said, in a new draft guidance.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor